Article details
Almujtama Alraida Medical Co. has amended its SAR 45 million credit facility with Alinma Bank, reallocating the entire amount to the purchase of goods and canceling the portion previously allocated for capital expenditures. The original agreement, secured in January 2025, included SAR 35 million for goods and SAR 10 million for capital projects. The revision aims to enhance the company’s liquidity amid current operational needs, as disclosed in a statement to Tadawul.
This corporate action reflects the company’s strategic shift to prioritize working capital over long-term investments. For traders, the move could signal short-term financial flexibility but may raise questions about future capital spending plans. Investors should monitor how this adjustment impacts Almujtama Alraida’s operational efficiency and debt management.
For Saudi and Gulf investors, the amendment highlights the importance of liquidity management in healthcare sectors during economic fluctuations. Key metrics to watch include the company’s debt-to-equity ratio, cash flow trends, and quarterly revenue reports. The healthcare sector’s performance in the MENA region is closely tied to such corporate financial decisions.
